Morgan Stanley Schedule 13G passive stakes

Morgan Stanley and its subsidiary disclose a 13.0% beneficial ownership stake in First Trust Intermediate Duration Preferred & Income Fund.

Morgan Stanley and its affiliates have filed an amendment to their Schedule 13G, reporting a 7.9% beneficial ownership in Canada Goose Holdings Inc.'s Subordinate Voting Shares.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 5.6% of Six Flags Entertainment Corporation's common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an Amendment No. 3 to their Schedule 13G, disclosing an 8.4% beneficial ownership in Guggenheim Active Allocation Fund.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., reported a combined beneficial ownership of 6.5% of Core & Main, Inc.'s Class A Common Stock as of September 30, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, reported a 5.9% beneficial ownership stake in RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.'s Series A Preferred Stock.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, reported a 5.4% beneficial ownership stake in Virtus Convertible & Income Fund II's Series A Preferred Shares.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G, disclosing a beneficial ownership of 14.8% of Key Tronic Corp's common stock.

Morgan Stanley has filed an amendment to its Schedule 13G, reporting a 5.2% beneficial ownership stake in White Mountains Insurance Group Ltd.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, reported a 5.1% beneficial ownership stake in Nuveen Select Maturities Municipal Fund.

Morgan Stanley and its subsidiary have disclosed a 7.2% beneficial ownership stake in DouYu International Holdings Ltd, primarily through shared voting and dispositive power.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, disclose a combined 8.3% beneficial ownership in ClearBridge Energy Midstream Opportunity Fund Inc. via an amended Schedule 13G filing.

Morgan Stanley and its subsidiary, Atlanta Capital Management, have reported increased beneficial ownership in Insight Enterprises Inc. common stock, reaching 6.4% and 5.9% respectively.

Morgan Stanley and its subsidiary, Atlanta Capital Management, have filed an amended Schedule 13G disclosing their beneficial ownership of 6.1% and 5.4% respectively, of Envista Holdings Corp's common stock.

Morgan Stanley and its subsidiary, Parametric Portfolio Associates LLC, have disclosed a 5.3% beneficial ownership stake in abrdn Income Credit Strategies Fund.

Morgan Stanley and its subsidiary, Parametric Portfolio Associates LLC, disclosed a 10.2% beneficial ownership stake in Virtus Convertible & Income Fund II.

Morgan Stanley and its subsidiary have reduced their beneficial ownership in abrdn Income Credit Strategies Fund below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported ceasing to be beneficial owners of more than five percent of Rigel Pharmaceuticals Inc.'s common stock.

Morgan Stanley and its subsidiary have reported a reduction in their beneficial ownership of ESSA Pharma Inc. common shares to below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported a 10.5% beneficial ownership stake in Evoke Pharma Inc. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Chemomab Therapeutics Ltd.'s ordinary shares.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported a 10.4% beneficial ownership stake in Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust.

Morgan Stanley and its subsidiary have reported ceasing to be beneficial owners of more than five percent of BiomX Inc.'s common stock.

Morgan Stanley and its subsidiary have reported a beneficial ownership of 6.8% in Beta Bionics, Inc.'s common stock.

Morgan Stanley has disclosed a 5.1% beneficial ownership stake in Bloom Energy Corp's Class A Common Stock, held as a passive investment.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed beneficial ownership of 5.5% of Roivant Sciences Ltd.'s common shares.

Morgan Stanley reports a 6.2% beneficial ownership stake in White Mountains Insurance Group Ltd. common stock.

Morgan Stanley has reported a 5.7% beneficial ownership stake in FactSet Research Systems Inc., held in the ordinary course of business.

Morgan Stanley has disclosed a 6.7% beneficial ownership stake in C4 Therapeutics, Inc. common stock.

Morgan Stanley has disclosed a 5.1% beneficial ownership stake in Insight Enterprises Inc., holding over 1.6 million shares as a passive investment.